Composition:
Each coated tablet contains: Ibandronic acid (as monosodium Ibandronate monohydrate) 150 mg.
Therapeutic Action:
Osteoclast bone resorption inhibition.
Posology:
One 150 mg tablet once a month on the same date each month.
Presentations:
Containers containing 1, 2 and 3 tablets.